300485.SZ
赛升药业
SZSE · Healthcare · C 制造业 · CN
CNY 9.05
−8.68%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 402.6M | 404.7M | 416.5M | 476.6M | 734.5M |
| Cost of Revenue | 135.1M | 141.2M | 140.4M | 140.9M | 171.6M |
| Gross Profit | 267.6M | 263.5M | 276.1M | 335.6M | 562.9M |
| Operating Expenses | |||||
| R&D Expense | 66.0M | 69.5M | 46.2M | 77.7M | 100.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 51.8M | 53.0M | 57.5M | 62.2M | 61.1M |
| Selling & Marketing Expense | 147.0M | 144.5M | 141.6M | 230.4M | 368.8M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 273.0M | 275.4M | 250.6M | 376.7M | 538.9M |
| Cost and Expenses | 408.0M | 416.6M | 391.1M | 517.6M | 710.5M |
| Operating Income (EBIT) | (31.3M) | 12.4M | (83.0M) | 121.7M | 254.6M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (30.8M) | 12.3M | (83.6M) | 122.2M | 254.6M |
| Income Tax Expense | (3.4M) | 4.5M | (6.7M) | 25.8M | 52.0M |
| Bottom Line | |||||
| Net Income | (20.7M) | 14.6M | (68.9M) | 102.9M | 204.7M |
| Earnings from Cont. Ops | (27.3M) | 7.8M | (76.9M) | 96.4M | 202.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (20.7M) | 14.6M | (68.9M) | 102.9M | 204.7M |
| Per Share | |||||
| Basic EPS | (CN¥0.04) | CN¥0.03 | (CN¥0.14) | CN¥0.21 | CN¥0.43 |
| Diluted EPS | (CN¥0.04) | CN¥0.03 | (CN¥0.14) | CN¥0.21 | CN¥0.43 |
| Revenue Per Share | CN¥0.84 | CN¥0.83 | CN¥0.85 | CN¥0.97 | CN¥1.54 |
| Shares | |||||
| Basic Shares Outstanding | 480.8M | 485.7M | 491.8M | 490.1M | 476.1M |
| Diluted Shares Outstanding | 480.8M | 485.7M | 491.8M | 490.1M | 476.1M |
| Profitability Metrics | |||||
| EBITDA | — | 59.4M | (36.1M) | 170.1M | 302.1M |
| D&A | — | 47.0M | 46.9M | 48.4M | 47.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026